Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Additional capecitabine use in early-stage triple negative breast cancer patients receiving standard chemotherapy: a new era? A meta-analysis of randomized controlled trials

Fig. 4

A “NACT-guided mode” or a “Standard plus mode” in early-staged TNBC. A In a “NACT-guided mode”, early-staged TNBC patients with risk factors (i.e. T > 2 cm, or LN+, or young-onset (<40y), or high ki67 index) are recommended to receive standard NACT. After screening of NACT, patients with residual invasive tumor are strong candidates for additional 6–8 cycles capecitabine use. B In a “Standard plus mode”, standard CT plus capecitabine could be recommended to all early-staged TNBC patients with risk factors, according to the present evidences. For T1b-cN0M0 patients, additional capecitabine could also be considered and discussed with patients

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us